Table 2.
Demographic Information.
| Age / Sex | RT-PCR results | 1st and 2nd dose vaccine | 3rd dose vaccine | Months post-2nd dose, Prior to 3rd |
|---|---|---|---|---|
| 70-75 / M | Negative^ | BNT162b2 | BNT162b2 | 1 |
| 30-35 / M | Negative* | BNT162b2 | BNT162b2 | 7 |
| 60-65 / M | Negative* | BNT162b2 | BNT162b2 | 8 |
| 50-55 / M | N/A | BNT162b2 | BNT162b2 | 5 |
| 56-60 / F | Negative* | BNT162b2 | BNT162b2 | 6 |
| 60-65 / M | Negative^ | BNT162b2 | BNT162b2 | 7 |
| 50-55 / F | Negative* | BNT162b2 | BNT162b2 | 7 |
| 60-65/ M | N/A | BNT162b2 | BNT162b2 | 6 |
| 66-70 / F | Negative* | BNT162b2 | BNT162b2 | 6 |
| 60-65 / F | Negative^ | BNT162b2 | mRNA-1273 | 1 |
| 56-60/ F | Negative* | BNT162b2 | BNT162b2 | 7 |
| 70-75 / F | Negative~ | BNT162b2 | BNT162b2 | 5 |
| 70-75 / F | N/A | BNT162b2 | BNT162b2 | 6 |
| 76-80 / M | Negative* | BNT162b2 | BNT162b2 | 7 |
| 70-75 / F | Negative* | BNT162b2 | mRNA-1273 | 6 |
| 76-80 / F | N/A | BNT162b2 | mRNA-1273 | 6 |
| 60-65 / F | Negative* | BNT162b2 | mRNA-1273 | 5 |
| 66-70 / M | Negative^ | BNT162b2 | BNT162b2 | 6 |
| 40-45/ M | Negative^ | BNT162b2 | mRNA-1273 | 6 |
| 70-75 / M | Negative^ | mRNA-1273 | mRNA-1273 | 5 |
| 50-55 / F | N/A | BNT162b2 | mRNA-1273 | 3 |
| 70-75 / F | Negative* | BNT162b2 | BNT162b2 | 6 |
| 36-40 / F | Negative* | BNT162b2 | mRNA-1273 | 4 |
^ = TaqPath (Thermo Fisher)
* = Abbott Real Time SARS-CoV-2
~ = PerkinElmer SARS-CoV-2 Real-Time RT-PCR assay
NA = Not Available; participants denied having COVID-19 or being exposed.
Demographic information for 23 study participants who received a 3rd RNA Vaccine Dose. Twenty-two individuals received two doses of BNT162b2 and one individual received two mRNA-1273 doses initially. 15 of the 22 individuals that were originally vaccinated with BNT162b2 obtained a 3rd dose of BNT162b2, and 8 received mRNA-1273 (100 µg) as their 3rd dose. One individual originally vaccinated with mRNA-1273 received a 3rd, 100 µg dose of mRNA-1273. All participants had either confirmed negative RT-PCR results or no known history of infection prior to enrollment. RT-PCR platform indicated using symbols defined below Table S1. Age ranges are provided to protect the identities of the individuals in the study.